Abatacept treatment of patients with primary Sjögren's syndrome results in a decrease of germinal centres in salivary gland tissue.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Clinical and Experimental Rheumatology

• Publication date

  2017-03-15

• Fields of study

  Medicine

• Identifiers
  PMID 27908305
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Non-proliferating plasma cells detected in the salivary glands and bone marrow of autoimmune NOD.B10.H2b mice, a model for primary Sjögren’s syndrome

  2016cited by this paper
• One year in review 2016: Sjögren's syndrome.

  2016cited by this paper
• CD28 Promotes Plasma Cell Survival, Sustained Antibody Responses, and BLIMP-1 Upregulation through Its Distal PYAP Proline Motif

  2015cited by this paper
• Pathophysiology of T follicular helper cells in humans and mice

  2015cited by this paper
• Differentiation of follicular helper T cells by salivary gland epithelial cells in primary Sjögren's syndrome.

  2014cited by this paper
• Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI)

  2014cited by this paper
• Abatacept treatment reduces disease activity in early primary Sjögren's syndrome (open-label proof of concept ASAP study)

  2014cited by this paper
• The role of ectopic germinal centers in the immunopathology of primary Sjögren's syndrome: a systematic review.

  2013cited by this paper
• Evaluation of Histologic, Serologic, and Clinical Changes in Response to Abatacept Treatment of Primary Sjögren's Syndrome: A Pilot Study

  2013cited by this paper
• Persistence of immunoglobulin-producing cells in parotid salivary glands of patients with primary Sjögren's syndrome after B cell depletion therapy

  2012cited by this paper
• Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjögren's syndrome

  2011cited by this paper
• Abatacept Limits Breach of Self-Tolerance in a Murine Model of Arthritis via Effects on the Generation of T Follicular Helper Cells

  2010cited by this paper
• Follicular dendritic cells confirm lymphoid organization in the minor salivary glands of primary Sjögren's syndrome.

  2008cited by this paper
• Parotid gland biopsy compared with labial biopsy in the diagnosis of patients with primary Sjogren's syndrome.

  2007cited by this paper
• Abatacept

  2006cited by this paper
• Quantitative immunohistologic criteria are superior to the lymphocytic focus score criterion for the diagnosis of Sjögren's syndrome.

  1992cited by this paper

• Clinical trials and new therapies in Sjögren's disease.

  2026cites this paper
• Plasmablasts as Translational Biomarkers in Autoimmune Diseases: From Cellular Dynamics to Clinical Decision-Making

  2026cites this paper
• Safety and immunogenicity of the recombinant zoster vaccine in patients with rheumatoid arthritis using abatacept: a pilot multicentre, double-blind, randomised controlled trial.

  2026cites this paper
• Increasing the number of minor salivary glands from patients with Sjögren's disease improves the diagnostic and measurement precision of the histological focus score.

  2025cites this paper
• Clinical targeted treatment in Sjogren's disease: A systematic literature review for an evidence-based medicine approach.

  2025cites this paper
• Circulating Tfh cells are differentially modified by abatacept or TNF blockers, and predict treatment response in Rheumatoid Arthritis.

  2024cites this paper
• More severe parotid gland histopathology in paediatric-onset than in adult-onset Sjögren’s disease

  2024cites this paper
• Salivary gland biopsy as a prognostic tool in Sjögren’s syndrome

  2024cites this paper
• Precision medicine in Sjögren's disease.

  2024cites this paper
• The Spectrum of Extraglandular Manifestations in Primary Sjögren’s Syndrome

  2023cites this paper
• Effect of DMARDs on the immunogenicity of vaccines

  2023cites this paper
• Role of JAK-STAT signaling pathway in pathogenesis and treatment of primary Sjögren's syndrome

  2023cites this paper
• Long-term abatacept treatment for 48 weeks in patients with primary Sjögren's syndrome: The open-label extension phase of the ASAP-III trial.

  2022cites this paper
• Recent Advances of Salivary Gland Biopsy in Sjögren's Syndrome

  2022cites this paper
• Sjögren’s syndrome: shedding light on emerging and key drug targets

  2022cites this paper
• Ultrasound-guided core needle biopsy and incisional biopsy of the parotid gland are comparable in diagnosis of primary Sjögren's syndrome.

  2022cites this paper
• Composition and regulation of the immune microenvironment of salivary gland in Sjögren’s syndrome

  2022cites this paper
• New developments in Sjogren’s syndrome

  2021cites this paper
• Cellular and molecular diversity in Sjogren's syndrome salivary glands: Towards a better definition of disease subsets.

  2021cites this paper
• Biological Therapy in Primary Sjögren's Syndrome: Effect on Salivary Gland Function and Inflammation

  2021cites this paper
• Innate Immunity and Biological Therapies for the Treatment of Sjögren’s Syndrome

  2020influential citation
• Targeted therapies in systemic sclerosis, myositis, antiphospholipid syndrome, and Sjögren's syndrome.

  2020cites this paper
• Is it the end of the road for abatacept treatment in Sjögren's syndrome?

  2020cites this paper
• Abatacept treatment for patients with early active primary Sjögren's syndrome: a single-centre, randomised, double-blind, placebo-controlled, phase 3 trial (ASAP-III study).

  2020cites this paper
• [Primary Sjögren's Syndrome - News on Diagnostics and Therapy].

  2020cites this paper
• Expression of BAFF and BAFF receptors in primary Sjögren’s syndrome patients with ectopic germinal center-like structures

  2020cites this paper
• Blocking T cell co-stimulation in primary Sjögren's syndrome: rationale, clinical efficacy and modulation of peripheral and salivary gland biomarkers.

  2020cites this paper
• Investigative biological therapies for primary Sjögren’s syndrome

  2020cites this paper
• T Cells Subsets in the Immunopathology and Treatment of Sjogren’s Syndrome

  2020cites this paper
• Sjögren's syndrome : Challenges of a multifaceted disease

  2020cites this paper
• Efficacy of rituximab for glandular Sjö gren's disease according to international clinical trials

  2020cites this paper
• University of Birmingham CXCL13 as biomarker for histological involvement in Sjögren’s Syndrome

  2019cites this paper
• CXCL13 as biomarker for histological involvement in Sjögren's syndrome.

  2019cites this paper
• Sjogren’s Syndrome

  2019cites this paper
• Abatacept modulates CD80 and CD86 expression and memory formation in human B-cells.

  2019cites this paper
• Present and novel biologic drugs in primary Sjögren's syndrome.

  2019cites this paper
• Sjögren-Syndrom bei Kindern und Jugendlichen

  2018cites this paper
• T cell-dependent B cell hyperactivity in primary Sjögren's syndrome: Biomarker and target for treatment

  2018cites this paper
• Can ultrasound of the major salivary glands assess histopathological changes induced by treatment with rituximab in primary Sjögren’s syndrome?

  2018cites this paper
• Advances in salivary gland ultrasonography in primary Sjögren's syndrome.

  2018cites this paper
• The role of salivary gland histopathology in primary Sjögren's syndrome: promises and pitfalls.

  2018cites this paper
• Discrepancy between subjective symptoms, objective measures and disease activity indexes: the lesson of primary Sjögren's syndrome.

  2018cites this paper
• University of Groningen The value of rituximab treatment in primary Sjögren's syndrome

  2017cites this paper
• The value of rituximab treatment in primary Sjögren's syndrome.

  2017cites this paper
• Attenuation of Follicular Helper T Cell–Dependent B Cell Hyperactivity by Abatacept Treatment in Primary Sjögren's Syndrome

  2017cites this paper
• One year in review 2017: primary Sjögren's syndrome.

  2017cites this paper
• FcRL4+ B-cells in salivary glands of primary Sjögren's syndrome patients.

  2017cites this paper
• Abatacept attenuates T follicular helper-cell-dependent B-cell hyperactivity in primary Sjögren's syndrome.

  2017cites this paper